10.1  0.01 (0.1%)		07-24 16:00
Open: 10.1 High: 10.1 Volume: 217		Pre. Close: 10.09 Low: 10.09 Market Cap: 530(M)

Short term
Mid term
Targets	6-month :	11.8	1-year :	13.79
Resists	First :	10.1	Second :	11.8
Pivot price	10.09
Supports	First :	10.07	Second :	10.05
MAs	MA(5) :	10.09	MA(20) :	10.08
	MA(100) :	10.03	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	58.3	D(3) :	51.6
RSI	RSI(14): 57.5
52-week	High :	10.1	Low :	9.85

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DMII ] has closed below upper band by 14.4%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	10.11 - 10.16	10.16 - 10.2
Low:	9.97 - 10.03	10.03 - 10.08
Close:	10.01 - 10.1	10.1 - 10.18

Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.

Tue, 26 May 2026
Drugs Made In America Acquisition II Corp. (DMII) Holds Steady Near Resistance: A Detailed Analysis - ATR Trailing Stop - dars.gov.et

Wed, 08 Apr 2026
Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics - Investing.com

Thu, 30 Oct 2025
Challenging Pfizer, Novo Nordisk Offers Up-to-$9B for Metsera - Genetic Engineering and Biotechnology News

Wed, 08 Oct 2025
Families of Trump and commerce secretary stand to benefit from U.S. drug overhaul: WSJ - Seeking Alpha

Thu, 25 Sep 2025
Drugs Made In America Acquisition II (DMIIU) Stock Price, News & Analysis - Stock Titan

Thu, 25 Sep 2025
Loeb Represents Drugs Made In America Acquisition II in $500 Million IPO - Loeb & Loeb LLP

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	64 (M)
Shares Float	50 (M)
Held by Insiders	15.2 (%)
Held by Institutions	70.4 (%)
Shares Short	59 (K)
Shares Short P.Month	65 (K)

EPS	0.12
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.29
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	77.69
PEG Ratio	0
Price to Book value	-36.08
Price to Sales	0
Price to Cash Flow	-579.62

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.